# Enoxaparin Sodium Injection IP 60mg/0.6 ml and 40mg/0.4 ml

**(Subcutaneous route, Intravascular route during Haemodialysis)**

## Manufacturing Technology:

The Enoxaparin Sodium crude drug is dissolved in the cooled water for injection maintaining all the temperature and pH conditions, manufactured through aseptic filtration and filled in a pre-filled syringe.

**Manufactured under WHO, European-GMP and Russian GMP approved facility located in Hyderabad.**




**MRP for 60 mg/0.6 ml- ₹640**
**MRP for 40 mg/0.4 ml- ₹426**

Advanov Pharma Pvt. Ltd.

202-203 Empire Business Hub, Science City Road,
Ahmedabad-380061,Gujarat, India

**Contact us:+91 79 4842 1299 / +91 98795 79801**

# INDICATIONS:

- Prophylaxis of venous thromboembolism in general medical patients bedridden due to acute illnesses including acute heart failure, respiratory failure, severe infections, rheumatic disease[1]

- Treatment of venous thromboembolic disease[2]

- Prevention of thrombus formation in the extra-corporeal circulation during haemodialysis[3]

- Treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin[4]

- Treatment of acute ST-segment Elevation Myocardial Infarction (STEMI) including patients to be managed medically or with subsequent Percutaneous Coronary Intervention (PCI)[5]

1,2 Comparison of Enoxaparin and Warfarin for the Prevention of Venous Thromboembolic Disease After Total Hip 2 Arthroplasty. Evaluation During Hospitalization and Three Months After Discharge*, Journal of Bone and Joint Surgery, 1997

3 Use of enoxaparin to diminish the incidence of vascular access stenosis/thrombosis in chronic hemodialysis patients, 2010

4 Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non–Q-Wave Myocardial Infarction, Circulation, 1999

5 Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction, DGA, Cardiovascular Biology and Cell Signalling, 2008